



Laboratory test results for patients 1, 2, and 3 at admission and after one year of treatment (in parentheses)

Patient 1

Erythrocytes, 4.97 (4.53) million/mm³; hemoglobin, 13.8 (14.4) g/dL; hematocrit, 41.9% (43.4%); leukocytes, 7,300 (6,400) /mm³; band neutrophils, 5% (3%); segmented neutrophils, 57% (43%); neutrophils, 66% (48%); eosinophils, 5% (6%); lymphocytes, 18% (34%);

atypical lymphocytes, 0% (0%); monocytes, 11% (11%); platelets, 455,000 (241,000) / mm³; total bilirubin, 0.4 (0.7) mg/dL; indirect bilirubin, 0.2 (0.5) mg/dL; direct bilirubin, 0.2 (0.2) mg/dL; aspartate aminotransferase (AST), 24 (32) U/L; alanine aminotransferase (ALT), 16 (16) U/L; total protein, 7.28 (7.33) g/dL; albumin, 3.28 (4.02) g/dL; globulin, 4.00 (3.31) g/dL; amylase, 83 (109) U/dL; alkaline phosphatase, 50 (29) U/L; lactate dehydrogenase (LDH), 371 (353) U/L; glucose, 79 (79) mg/dL; urea, 18 (42) mg/dL; creatinine, 0.6 (0.6) mg/




Figure 1. Posteroanterior and lateral chest X-rays of patient 1. In A, initial chest X-rays taken on October 1, 2013. In B, chest X-rays taken after one year of treatment, on November 18, 2014.

dL; uric acid, 10.5 (3.3) mg/dL; sodium, 139 (143) mEq/L; potassium, 4.2 (4.9) mEq/L; calcium, 7.9 (10.2) mg/dL; serology for syphilis (venereal disease research laboratory—VDRL—test), negative; HBV serology (Australia hepatitis B surface antigen—HBsAg—screening), 0.746 (negative); HCV serology (anti-HCV screening), negative; HIV-1/2 serology, negative; fungal serology, negative; urine culture, negative; electrocardiogram (ECG), within normal limits for age.

Patient 2

Erythrocytes, 4.20 (4.67) million/mm³; hemoglobin, 12.6 (15.1) g/dL; hematocrit, 37.8% (41.7%); leukocytes, 9,200 (9,100) /mm³; band neutrophils, 0%

(0%); segmented neutrophils, 64% (40%); neutrophils, 64% (40%); eosinophils, 4% (6%); lymphocytes, 26% (46%); atypical lymphocytes, 0% (1%); monocytes, 6% (7%); platelets, 304,000 (237,000) /mm³; total bilirubin, 0.6 (0.9) mg/dL; indirect bilirubin, 0.5 (0.7) mg/dL; direct bilirubin, 0.1 (0.2) mg/dL; AST, 17 (28) U/L; ALT, 8 (11) U/L; total protein, 7.01 (6.06) g/dL; albumin, 3.66 (3.91) g/dL; globulin, 3.35 (2.15) g/dL; amylase, 49 (89) U/dL; alkaline phosphatase, 60 (33) U/L; LDH, 328 (373) U/L; glucose, 110 (84) mg/dL; urea, 18 (18) mg/dL; creatinine, 0.8 (0.7) mg/dL; uric acid, 3.3 (3.6) mg/dL; sodium, 139 (139) mEq/L; potassium, 4.0 (4.2) mEq/L; calcium, 9.7 (10.1) mg/dL; VDRL test, negative; HBsAg screening, 0.484




Figure 2. Posteroanterior and lateral chest X-rays of patient 2. In A, initial chest X-rays taken on October 28, 2013. In B, chest X-rays taken after one year of treatment, on November 6, 2014.

(negative); anti-HCV screening, negative; HIV-1/2 serology, negative; fungal serology, negative; urine culture, negative; ECG, within normal limits for age.

Patient 3

Erythrocytes, 4.18 (4.48) million/mm³; hemoglobin, 9.3 (14.4) g/dL; hematocrit, 30.4% (42.5%); leukocytes, 10,900 (10,100) /mm³; band neutrophils, 1% (1%); segmented neutrophils, 71% (47%); neutrophils, 72% (48%); eosinophils, 1% (7%); lymphocytes, 21% (40%); monocytes, 6% (5%); platelets, 561,000 (299,000) /mm³; total bilirubin, 0.6 (0.3) mg/dL;

direct bilirubin, 0.1 (0.2) mg/dL; indirect bilirubin, 0.6 (0.1) mg/dL; AST, 26 (18) U/L; ALT, 14 (15) U/L; total protein, 7.00 (7.01) g/dL; albumin, 2.61 (3.98) g/dL; globulin, 4.39 (3.03) g/dL; amylase, 36 (58) U/L; alkaline phosphatase, 64 (55) U/L; LDH, 206 (74) U/L; glucose, 124 (84) mg/dL; urea, 21.0 (31.6) mg/dL; creatinine, 0.6 (0.6) mg/dL; uric acid, 4.0 (3.8) mg/dL; sodium, 137 (145) mEq/L; potassium, 3.6 (4.3) mEq/L; calcium, 8.9 (9.1) mg/dL; HIV-1/2 serology, negative; anti-HCV screening, negative; VDRL test, negative; HBsAg screening, negative; fungal serology, negative; parasitological examination, negative; urine culture, negative; ECG, within normal limits for age.




Figure 3. Posteroanterior and lateral chest X-rays of patient 3. In A, initial chest X-rays taken on February 12, 2014. In B, chest X-rays taken after one year of treatment, on March 18, 2015.